Back to Directory Clair Walker Email clair.x.walker@gsk.com Phone 44 208990 4950 Institution GSK Address GSK GSK House - Location CS3 980 Great West Road Brentford Middlesex, TW8 9GS United Kingdom Request an Update Affiliated Studies IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status Withdrawn
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status Withdrawn